Article Text
Statistics from Altmetric.com
We read with interest the recent study by Krebs et al demonstrating the limitations of StratusOCT mapping software in the context of age-related macular degeneration (AMD).1 We wish to applaud the authors for their study—while the limitations of StratusOCT automated analysis have previously been reported,2 the fact remains that many ophthalmologists may not be well acquainted with these errors. We agree with the authors and wish to underline the importance of these errors in this era of optical coherence tomography (OCT)-guided retreatment regimens for anti-angiogenic agents and increasing adoption of quantitative OCT measurements as secondary outcome parameters in clinical trials.3
In their study, the authors present evidence that automated Stratus software provides correct results in only 57.1% of eyes with AMD. …
Footnotes
Funding: Supported in part by NIH Grant EY03040 and NEI Grant R01 EY014375.
Competing interests: ACW and SRS are coinventors of Doheny intellectual property related to spectral domain optical coherence tomography that has been licensed by Topcon Medical Systems. However, it is not related to the article’s subject matter.